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Enterococci, which have been known as a
cause of infective endocarditis for close to a
century, more recently have been recognized as a
cause of nosocomial infection and “superinfec-
tion” in patients receiving antimicrobial agents
(1). The enterococcus is now receiving increased
attention because of its resistance to multiple
antimicrobial drugs, which probably explains a
large part of its prominence in nosocomial
infections. The most common enterococci-
associated nosocomial infections are infections of
the urinary tract, followed by surgical wound
infections and bacteremia (1-3). Enterococci are
often present in intraabdominal and pelvic
infections, although not all patients with such
infections require specific antienterococcal
therapy. Other enterococcal infections include
infections (including meningitis and bacteremia)
in very ill neonates; central nervous system
infections  in adults, typically with a history of
central nervous system surgery or intrathecal
chemotherapy; and rarely, osteomyelitis and
pulmonary infections. Enterococci frequently
arise from colonization of indwelling T tubes,
causing liver or biliary infection in liver
transplant patients (1).
Antimicrobial Resistance
Most enterococci have naturally occurring or
inherent resistance to various drugs, including
cephalosporins and the semisynthetic penicillinase-
resistant penicillins (e.g., oxacillin) and clinically
achievable concentrations of clindamycin and
aminoglycosides. Compared with streptococci,
most enterococci are relatively resistant to
penicillin, ampicillin, and the ureidopenicillins,
with MICs of 1 mg/ml to 8 mg/ml for most
Enterococcus faecalis and even higher for most
E. faecium. Many enterococci are also tolerant
to the killing effects of cell-wall active agents,
including ampicillin and vancomycin; recent data
suggest that this property may not be inherent,
but rather acquired after exposure to antibiotics
(4). Inherent in vivo resistance of E. faecalis to
trimethoprim-sulfamethoxazole may explain the
lack of efficacy in animal models. In vitro,
trimethoprim-sulfamethoxazole readily inhibits
most enterococci at low concentrations, but this
activity is lessened by exogenous folates (5).
Moreover, bactericidal activity against E. faecalis
seems unreliable and very method dependent (6).
In animal models, this combination has not
shown good activity and is not generally accepted
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Enterococci are associated with both community- and hospital-acquired infections.
Even though they do not cause severe systemic inflammatory responses, such as
septic shock, enterococci present a therapeutic challenge because of their resistance
to a vast array of antimicrobial drugs, including cell-wall active agents, all commercially
available aminoglycosides, penicillin and ampicillin, and vancomycin. The combination
of the latter two occurs disproportionately in strains resistant to many other
antimicrobial drugs. The propensity of enterococci to acquire resistance may relate to
their ability to participate in various forms of conjugation, which can result in the spread
of genes as part of conjugative transposons, pheromone-responsive plasmids, or
broad host-range plasmids. Enterococcal hardiness likely adds to resistance by
facilitating survival in the environment of a multidrug-resistant clone,  thus enhancing
potential spread from person to person. The combination of these attributes within the
genus Enterococcus suggests that these bacteria and their resistance to antimicrobial
drugs will continue to pose a challenge.38 Emerging Infectious Diseases Vol. 4, No. 1, January–March 1998
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as an effective antienterococcal therapy, espe-
cially for systemic infections (7,8).
In addition to natural resistance to many
agents, enterococci have also developed plasmid-
and transposon-mediated resistance to tetracy-
cline (as well as minocycline and doxycycline),
erythromycin (plus the newer compounds
azithromycin and clarithromycin), chloram-
phenicol, high levels of trimethoprim, and high
levels of clindamycin.
The propensity of E. faecalis to acquire
multiple antibiotic-resistance traits may result
from a variety of distinctly different mechanisms
for conjugation, i.e., bacterial mating. The best
studied system of conjugation involves
oligopeptides called pheromones and pheromone-
responsive plasmids (9; Figure 1).  Briefly, strains
of  E. faecalis typically secrete into the culture
medium a number of different small peptide sex
pheromones specific for different types of
plasmids. When a cell containing a pheromone-
responsive plasmid (the potential donor cell)
comes into contact with its corresponding
pheromone, transcription of a gene on the
plasmid is turned on, resulting in the synthesis of
a sticky substance (called aggregation substance)
on its surface. When the donor cell bumps into
another  E. faecalis, aggregation substance,
which contains two Arg-Gly-Asp motifs, sticks to
the binding substance on the surface of most
E. faecalis cells, causing them to clump together.
In the test tube, clumps of cells actually fall to the
bottom of the tube, resulting in a visible
aggregate. By a process not yet well understood,
the pheromone-responsive plasmid can then
transfer from the donor bacterium to the other
(recipient) bacterium. Once the recipient cell has
acquired this particular plasmid, the synthesis of
the corresponding sex pheromone is shut off to
prevent self-clumping. This system of conjuga-
tion, which occurs primarily in E. faecalis, is
highly efficient and results in transfer of
plasmids in both filter and broth matings.
Another system of conjugation, also not well
understood, involves broad host-range plasmids
that can transfer among species of enterococci
and other gram-positive organisms such as
streptococci and staphylococci (10). The transfer
frequency is generally much lower than with the
pheromone system and is much more efficient
with filter than with broth matings. Since
staphylococci, streptococci, and enterococci share
a number of resistance genes, these broad host-
range plasmids may be a mechanism by which
some of these resistance genes have spread
among different genera.
A third type of conjugation, which involves
conjugative transposons, may also explain the
spread of resistance genes to many different
species (11). As opposed to ordinary transposons,
which can jump within a cell from one DNA
location to another, conjugative transposons also
encode the ability to bring about conjugation
between different bacterial cells. Since plasmids
typically require rather complex machinery for
replication (often depending on successful
interactions with host proteins) and must face
additional problems of surface exclusion and
incompatibility, conjugative transposons (which
do not replicate, but instead insert into the
chromosome or into a plasmid of the new host)
appear to be an even more efficient and far-
reaching way of disseminating a resistance gene.
This may explain why the tetM gene of the
conjugative transposon Tn916 has spread beyond
the gram-positive species into gram-negative
organisms, including gonococci, meningococci,
and Haemophilus ducreyi, as well as into
mycoplasma and ureaplasma, among others
(12,13). Other resistance genes, including those
encoding resistance to erythromycin and kana-
mycin, are also found on conjugative transposons;
these frequently contain or are related to Tn916.
Such transposons may have evolved from a
Tn916 ancestor; their emergence suggests the
Figure 1. Enterococcus faecalis pheromone-responsive
conjugative system.
Pheromone A released from the potential recipient cell
(right) interacts with plasmid A in the potential donor
cell (left) to induce synthesis of aggregation substance.
Attachment of aggregation substance to binding
substance causes the cells to clump into visible
aggregates. Once the pheromone-responsive plasmid
A has transferred from donor to recipient cell,
synthesis of pheromone A is shut off.39 Vol. 4, No. 1, January–March 1998 Emerging Infectious Diseases
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possibility of further dissemination of resistance
among gram-positive organisms. Particularly
ominous are reports of the vanB gene cluster
within large conjugative chromosomal elements
that appear similar, at least in function, to
conjugative transposons (14).
High-Level Aminoglycoside Resistance
Although some acquired resistance of
enterococci is not clinically important because
the agents involved are not commonly used, other
resistance greatly affects enterococcal therapy;
high-level resistance (HLR) to aminoglycosides is
an example. This resistance is added onto the
normal low-level resistance of enterococci to
aminoglycosides and typically results in MICs of
> 2,000 mg/ml. This degree of resistance predicts,
without exception, resistance to synergism between
cell-wall active agents and the aminoglycoside to
which the organism is highly resistant (1). High-
level aminoglycoside resistance is most often due
to aminoglycoside-modifying enzymes; HLR to
streptomycin can also be ribosomal, that is, due to
a mutation that results in ribosomes resistant to
streptomycin inhibition. HLR to kanamycin
(without gentamicin) is a fairly common trait and
is due to the production of a 3'-phosphotransferase,
APH(3')-III. This enzyme is important because it
also eliminates synergism between cell-wall
active agents and amikacin (through phosphory-
lation of the 3'-hydroxyl group), although it does
not necessarily confer HLR to amikacin. HLR to
gentamicin results from the bifunctional protein
(AAC(6')-I/APH(2")-I), encoded by a single gene
with two active sites, one with 6'-acetyltransferase
activity and the other, 2"-phosphotransferase
activity (15). The combination of these activities
results in HLR or resistance to synergism for all
commercially available aminoglycosides except
streptomycin, which is not modified by this
enzyme. However, HLR to streptomycin (due to
either ribosomal resistance or a streptomycin
adenylyltransferase) is also common and can
coexist with the gene(s) for HLR to other
aminoglycosides. Spectinomycin is also not
modified by the bifunctional enzyme, but this
agent, which is not a true aminoglycoside, is not
generally bactericidal against enterococci and
does not appear to show synergism with cell-
wall active agents.
Strains of enterococci from patients with
endocarditis and other serious infections for
whom combination therapy is desired should be
screened for HLR to streptomycin and gentami-
cin. HLR screening for tobramycin is not
generally performed or advisable It could, in
principle, be used for E. faecalis, but E. faecium
isolates have a chromosomally encoded, natu-
rally occurring gene for a 6'-acetyltransferase
that eliminates synergism with tobramycin,
although it does not cause HLR (MICs are
typically 128-500 mg/ml); a probe for this gene has
been used to confirm the identification of E.
faecium isolates to species. In addition, HLR of an
E. faecium isolate (without HLR to gentamicin) to
tobramycin, due to an adenylyltransferase, was
recently described (16). Therefore, the use of
tobramycin for possible synergism in serious
enterococcal infections would need to be preceded
by screening for HLR to tobramycin (a test that is
not commonly available), as well as for identifica-
tion to species, neither of which is practical.
More recently, veterinary and human isolates
resistant to moderate levels of gentamicin (256 mg/
ml) were found to have a new gentamicin-modifying
enzyme encoded by a gene designated aph(2")-Ic
(17). This gene conferred resistance to synergism
between gentamicin and cell-wall active agents and
may be less easily detected than strains producing
the bifunctional enzyme.
Beta-Lactamase– and non-Beta-Lactamase–
Associated Penicillin Resistance
The first known penicillinase-producing
isolate of enterococcus was an isolate of E.
faecalis recovered from a patient in Houston,
Texas, in 1981 (18). Although rare, these isolates
have been reported from the United States
(Texas, Florida, North Carolina, Delaware,
Pennsylvania, New York, Massachusetts, and
Connecticut), Lebanon, Canada, and Argentina
(19). Like other enterococci, beta-
lactamase-producing strains have been found as
colonizers, as in the large “outbreak” of
colonization in a Boston children’s hospital, but
they have also been associated with true
infections, as was demonstrated by cases at a
Virginia Veterans Administration hospital, by
isolates from Argentina, and in other reports
(20,21). The enterococcal penicillinase gene,
identical to the gene encoding staphylococcal
type A penicillinase, almost always occurs in
strains with HLR to gentamicin and is often
found on a transferable plasmid that also
contains  aph(2")-Ia/aac(6')-Ie. The relatively low
levels of beta-lactamase produced by enterococci40 Emerging Infectious Diseases Vol. 4, No. 1, January–March 1998
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result in a marked inoculum effect with these
strains so that at low and even moderate inocula
(103-105 CFU/ml), penicillinase-producing en-
terococci usually appear no more resistant than
other enterococci, while at high inocula (> 107
CFU/ml), these organisms are usually highly
resistant to penicillin, ampicillin, and
ureidopenicillins. The activity of the penicillinase
is reversed by the beta-lactamase inhibitors
clavulanate, sulbactam, and tazobactam; in
animal models of endocarditis, beta-lactamase
inhibitors have been shown to markedly enhance
the therapeutic efficacy of ampicillin or penicil-
lin. In the clinical laboratory, penicillinase-
producing enterococci are generally not detected
by routine laboratory susceptibility testing,
such as MICs or disk diffusion. For this reason,
if a penicillin is to be used for therapy,
enterococcal isolates from patients with
endocarditis or other serious infections should
be tested for penicillinase production by using a
specific beta-lactamase test such as the
chromogenic cephalosporin nitrocefin.
Nonpenicillinase-producing, penicillin-resistant
enterococci have been reported for decades and
usually are E. faecium. Until recently, MICs of
penicillin typically ranged from 8 mg/ml to 64 mg/ml,
with an occasional isolate having higher levels of
resistance. However, increasingly, strains with
much higher levels of penicillin resistance have
been reported (22). Whether a large number of
strains have converted from low-level to high-level
resistance or a more limited number of strains have
been disseminated is unclear. The mechanisms
involved in this resistance are overproduction of a
low-affinity penicillin-binding protein (a cell-wall
synthesis enzyme) and a further decrease in the
affinity of one of these enzymes for penicillin (23).
As a possible explanation for why many
vancomycin-resistant  E. faecium also have very
high levels of resistance to ampicillin, Rice and
colleagues (24) showed that transfer of vancomycin
resistance from one strain to another was linked to
transfer of ampicillin resistance.
Vancomycin Resistance
Most surprising in recent years has been the
emergence among enterococci of acquired resis-
tance to vancomycin. Vancomycin had been in
clinical  use since the 1950s, although it was not
heavily used until the late 1970s and particularly
the 1980s. Because multiple genes are involved in
generating vancomycin resistance, the development
of resistance was neither easy nor recent. Three
phenotypes of vancomycin resistance (types A, B,
and C) are now well described; a fourth, type D,
has been recently reported (25). VanA-type
strains are typically highly resistant to vancomy-
cin and moderately to highly resistant to
teicoplanin. This phenotype is often plasmid or
transposon mediated and is inducible (i.e.,
exposure of bacteria to vancomycin results in the
induction of the synthesis of several proteins that
together confer resistance) (26).
In vancomycin-susceptible enterococci, D-
alanyl-D-alanine (formed by an endogenous D-
alanine-D-alanine ligase) is added to a tripeptide
precursor to form a pentapeptide precursor. The
D-Ala-D-Ala terminus is the target of vancomy-
cin; once vancomycin has bound, the use of this
pentapeptide precursor for further cell-wall
synthesis is prevented. In the VanA phenotype,
one of the proteins whose synthesis is induced by
exposure of bacterial cells to vancomycin is called
VanA; VanA is a ligase and resembles the D-
alanine-D-alanine ligase from Escherichia coli
and other organisms, including vancomycin-
susceptible enterococci (27). VanA generates D-
Ala-D-X, where X is usually lactate; the
formation of D-lactate is due to the presence of
VanH, a dehydrogenase encoded by vanH. The
depsipeptide moiety, D-Ala-D-Lac, is then added
to a tripeptide precursor, resulting in a
depsipentapeptide precursor. Vancomycin does
not bind to the D-Ala-D-Lac terminus, so this
depsipentapeptide can be used in the remaining
steps of cell-wall synthesis. However, when the
normal pentapeptide precursor ending in D-Ala-
D-Ala is also present, cells are not fully
vancomycin resistant, despite the presence of D-
Ala-D-Lac containing precursors. This apparent
problem is taken care of in large part by vanX,
which encodes a dipeptidase, VanX, that cleaves
D-Ala-D-Ala, preventing its addition to the
tripeptide precursor. Should any D-Ala-D-Ala
escape cleavage and result in a normal
pentapeptide precursor, vanY encodes an ancil-
lary or back-up function. That is, it codes for a
carboxypeptidase, VanY, which cleaves D-
alanine and D-lactate from D-Ala-D-Ala and D-
Ala-D-Lac termini, respectively, resulting in
tetrapeptide precursors, to which vancomycin
does not bind. The other genes involved in the
VanA resistance complex include vanR and vanS,
whose encoded proteins are involved in somehow
sensing the presence of extracellular vancomycin or41 Vol. 4, No. 1, January–March 1998 Emerging Infectious Diseases
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its effect and signaling intracellularly to activate
transcription of vanH, vanA, and vanX (27). A final
gene in the vanA cluster is vanZ, which encodes
VanZ, the role of which is not known.
VanB, encoded by vanB in the vanB gene
cluster, is also a ligase that stimulates the
formation of D-Ala-D-Lac. The VanB phenotype
is typically associated with moderate to high
levels of vancomycin resistance but is without
resistance to teicoplanin. This is explained by the
observation that vancomycin, but not teicoplanin,
can induce the synthesis of VanB and of VanHB
and VanXB. However, because mutants resistant
to teicoplanin can readily be selected from VanB
strains on teicoplanin-containing agar, clinical
resistance would likely occur among VanB strains if
teicoplanin were widely used. Most of the proteins
encoded by the vanA gene cluster have homologues
encoded by the vanB gene cluster, except for VanZ.
The  vanB gene cluster has an additional gene,
vanW, of unknown function.
The VanC phenotype (low-level resistance to
vancomycin, susceptible to teicoplanin) is an
inherent (naturally occurring) property of E.
gallinarum and E. casseliflavus. This property is
not transferable and is related to the presence of
species-specific genes vanC-1 and vanC-2,
respectively (28); a third possible species, E.
flavescens and its gene vanC-3, are so closely
related to E. casseliflavus and vanC-2 that
different names are probably not warranted (29).
These species appear to have two ligases; the cell-
wall pentapeptide, at least in E. gallinarum, ends
in a mix of D-Ala-D-Ala and D-Ala-D-Ser (29,30).
The genes vanC-1 and vanC-2 apparently lead to
the formation of D-Ala-D-Ser containing cell-wall
precursors, while D-Ala-D-Ala ligases, also
present in these organisms, result in D-Ala-D-
Ala. The presence of both D-Ala-D-Ala and D-Ala-
D-Ser precursors may explain why many isolates
of these species test susceptible to vancomycin
and why even those isolates with decreased
susceptibility display only low-level resistance.
VanD-type glycopeptide resistance has been
recently described in an E. faecium isolate from
the United States (25). The organism was
constitutively resistant to vancomycin (MIC ³ ³ ³ ³ ³ 64
mg/ml) and to low levels (4 mg/ml) of teicoplanin.
Following polymerase chain reaction amplifica-
tion with primers that amplify many D-Ala-D-Ala
ligases, a 605-bp fragment was identified whose
deduced amino acid sequence showed 69% identity
to VanA and VanB and 43% identify to VanC.
Molecular Epidemiology of Newer
Resistance Traits
High-Level Gentamicin Resistance
The DNA sequence of the gene encoding HLR
to gentamicin in E. faecalis is the same as the
sequence of the gentamicin resistance gene of
staphylococci (15). Since this gene was well
established in staphylococci by the 1970s but
HLR to gentamicin was not reported in
enterococci until 1979, the seemingly obvious
conclusion is that this gene spread from
staphylococci to enterococci rather than vice
versa or, at least, staphylococci acquired it first.
However, the disk diffusion method used in the
1970s and microtiter dilution MICs done later are
capable of detecting gentamicin resistance in
staphylococci but do not distinguish enterococci
with high-level gentamicin resistance from those
with low-level, inherent resistance. Therefore,
since laboratories were not screening enterococci
by special techniques for high-level gentamicin
resistance, it cannot be definitively stated that
this resistance did not appear in enterococci
earlier or coincident with its emergence in
staphylococci. However, several observations
support the likelihood that gentamicin resistance
appeared and disseminated in staphylococci
before it did in enterococci. In 1971, Moellering et
al. reported the lack of high-level gentamicin
resistance among enterococci (31).
Watanakunakorn reported the absence of high-
level gentamicin resistance among 126 entero-
cocci from 1980 to 1984, with HLR subsequently
appearing in 1985 (32). Phillips et al. from the
United Kingdom reported no highly gentamicin-
resistant strains in 1969 to 1979 or 1980 to 1985
and appearance of strains in 1986 (33). Zervos et
al. reported that only one (0.04%) of 269 isolates
of  E. faecalis had high-level gentamicin resis-
tance in 1981; this figure gradually increased to
7.7% in 1984 (34). High-level gentamicin
resistance in E. faecium appears to have occurred
after its appearance in E. faecalis, with the first
report occurring in 1988 (35).
Delineation of the molecular epidemiology of
strains of enterococci was limited in the past by
the lack of an easy, reliable, and widely accessible
method for subspecies strain differentiation.
Zervos and Schaberg reported the use of plasmid
patterns in enterococci to suggest the intrahospital
spread of strains with high-level gentamicin
resistance. Pulsed-field gel electrophoresis (PFGE)42 Emerging Infectious Diseases Vol. 4, No. 1, January–March 1998
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of E. faecalis with HLR to gentamicin found that
different isolates from both the same and
different locations had markedly different
restriction endonuclease digestion patterns. That
is, it found no evidence of a common strain or
strains that predominated among gentamicin-
resistant organisms (36). Strains isolated be-
tween 1981 and 1984 at the University of
Michigan demonstrated that plasmids encoding
high-level gentamicin resistance were heteroge-
neous, which again argues against clonal
dissemination of a limited number of strains or
plasmids to account for spread of this property
(34,37). We have subsequently shown that
gentamicin resistance in enterococci can be
encoded on a transposon identical to that in
staphylococci (38). In addition, the enterococcal
gentamicin-resistance gene has been found in
other genetic settings, one of which has also been
found in North American Staphylococcus aureus
with gentamicin resistance (39). Since all
enterococci with HLR to gentamicin (MIC > 2,000
mg/ml) that have been tested have hybridized
with the same gene probe, this property could be
termed a “gene epidemic.” However, by the time
gentamicin resistance was discovered in entero-
cocci, this gene was already widespread with no
evidence of either a common plasmid or a
common or predominant strain.
Other genetic elements encoding HLR to
gentamicin have also been described. Thal et al.
have described a 27-kb element designated
Tn924 that encodes HLR to gentamicin and could
be mobilized from the chromosome of an E.
faecalis by a coresident plasmid (40). Rice et al.
have described a large (ca. 60 kb) transferable
element, tentatively named Tn5385, which
appears to contain within it an 18-kb conjugative
transposon (Tn5381) encoding tetracycline resis-
tance and a 26-kb IS256-based composite
transposon (Tn5384) encoding resistance to
gentamicin and to erythromycin (41).
Penicillin-Resistant Penicillinase-Producing
Enterococci
PFGE analyses of penicillinase-producing
enterococci have shown that a common penicilli-
nase-producing strain (or “clone”), defined as
having an identical or related chromosomal
digestion pattern, was present in Texas, Florida,
North Carolina (unpub. observation), Delaware,
Pennsylvania, and Virginia, which had a large
outbreak with numerous infections (42,43).
Moreover, at each of these locations, all isolates of
penicillinase-producing  E. faecalis examined
were derivatives of this strain; in the hospital in
which this strain has been endemic for many
years, a single penicillinase-producing isolate of
E. faecium, the only such isolate ever reported,
was also found (44). Among numerous non-Bla+
E. faecalis, a PFGE pattern similar to that of Bla+
E. faecalis has been found only once from an
isolate from a Philadelphia hospital that had one
of the Bla+ isolates (43 and unpub. obs.).
Penicillinase-producing isolates from Connecti-
cut, Boston, Canada (unpub. observations),
Lebanon, and Argentina represent different
strains (19). However, clonal relatedness of three
isolates with an almost identical pattern was
demonstrated in Connecticut (despite one of
these lacking HLR to gentamicin) (45), and all six
isolates in Argentina appeared to be a single
strain. The Boston isolates have not been studied
by PFGE, but a number of isolates from the same
hospital had a single shared plasmid, suggesting
that these also represent clonal dissemination of
a single strain. While all of these penicillinase-
producing  E. faecalis could be detected by
nitrocefin, a vancomycin-resistant E. faecalis
that tested negative for penicillinase by
nitrocefin but showed a marked inoculum effect
with penicillin and destroyed penicillin in a
bioassay has been reported (46). Thus, in contrast
to high-level gentamicin resistance in entero-
cocci, which appeared to be widely disseminated
on different plasmids and in different strains by
the time this phenotype was studied, penicilli-
nase production in enterococci is still largely
associated with a limited number of strains;
moreover, in locations known to have more
than one isolate, oligoclonal spread within each
setting remains the rule.
Nonpenicillinase-Producing Penicillin-
Resistant Strains
PFGE analyses of highly penicillin-resistant
E. faecium from the Medical Colleges of Virginia
and Pennsylvania have shown that within each
location, most highly resistant strains repre-
sented a single clone (47). Analysis of the PFGE
patterns also raised the possibility, on the basis of
similarities between patterns of isolates in these
two different locations, that a strain may have
spread from one institution to the other (47); this
conclusion was supported by the finding that
these isolates belonged to the same multilocus43 Vol. 4, No. 1, January–March 1998 Emerging Infectious Diseases
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enzyme cluster (unpub. observations). Circum-
stantial evidence of intrahospital spread of highly
penicillin-resistant  E. faecium also comes from
the study of Grayson et al. (22), who reported a
sudden increase in more highly penicillin-
resistant isolates of E. faecium at the Massachu-
setts General Hospital in 1988. Although no
genetic analysis was done, the fact that
gentamicin resistance also simultaneously ap-
peared and most of the E. faecium highly
resistant to penicillin were also highly resistant
to gentamicin suggests clonal dissemination of
one or a few strains within that hospital (22).
Vancomycin Resistance
Vancomycin resistance in enterococci is
heterogeneous on many levels. For example,
three different, well-described types of vancomy-
cin resistance are known, each associated with
different ligase genes, (vanA, vanB, vanC1, and
vanC2), and a fourth type, VanD, has been
reported recently (25). VanA and VanB type
resistance is encoded by gene clusters that are
acquired (i.e., not part of the normal genome of
enterococci) and are often transferable. In contrast,
vanC1 and vanC2 are normally occurring genes
that are endogenous species characteristics of E.
gallinarum and E. casseliflavus, respectively, and
are not transferable. The acquired gene clusters
associated with vanA and vanB are found in
different genetic surroundings. The vanA gene
cluster has been found in a small Tn3-like
transposon, Tn1546, and in elements that appear to
be closely related (e.g., Tn5488, which has an
insertion sequence [IS1251] within Tn1546
[48,49]) or lacking vanZ (50). These elements
have in turn been found on both transferable and
nontransferable plasmids, as well as on the
chromosome of the host strain. VanB type
resistance was initially not found to be transferable,
but at least in some instances, the vanB gene cluster
has been found on large (90 kb to 250 kb)
chromosomally located transferable elements, one
of which contains within it a 64-kb composite
transposon (Tn1547) (Figure 2; 14). More recently,
vanB has been found as part of plasmids.
In addition to being found in different genetic
surroundings, the vanA and vanB gene clusters
have also been found in a number of different
bacterial species. vanA has been found in multiple
enterococcal species as well as in lactococci,
Orskovia, and Arcanobacteria (51). The distribution
of the vanB gene cluster seems somewhat more
restricted, having been found primarily in E.
faecium and E. faecalis, although it has recently
been found in Streptococcus bovis (52).
When vancomycin-resistant enterococci (VRE)
from patients in a given hospital have been
examined, particularly after the first recovery of
VRE, evidence is often found of a single or
predominant strain (53-58). Finding isolates with
identical or highly related PFGE patterns in
different hospitals indicates interhospital clonal
transmission (59-61). Some reports do not find a
single or a predominant strain, especially when
VRE have been present in a hospital or area for
some time (62,63). This was also true of two
reports from France in which all of 16 and all of 24
vancomycin-resistant  E. faecium were different
(50,64,65). The reports from France likely reflect
another observation regarding the diversity of
Figure 2. Potential modes of spread of vancomycin-
resistant genes. Adapted in part from Quintiliani and
Courvalin (14).
The vanB gene cluster (shown on the left) on a 64-kb
transposon is part of a 250-kb mobile element shown
to move from the chromosome of one enterococcus and
insert into the chromosome of another. Although not
demonstrated, circularization of the vanB containing
large mobile elements resembles the mechanism
described for conjugative transposons that can excise
from the chromosome of  one strain, circularize,
transfer from one enterococcus to another, and
reinsert into the chromosome of the recipient (such as
the one on the right). The 64-kb transposon shown on
the left can also jump to another plasmid within the
host enterococcus. If it is a conjugative (Tra+) plasmid,
that plasmid can then transfer by conjugation to other
bacteria, taking the van resistance genes with it. In
one instance, the vancomycin resistance transposon
was shown to transpose to a plasmid encoding the
virulence factor hemolysin (Hly).44 Emerging Infectious Diseases Vol. 4, No. 1, January–March 1998
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vancomycin resistance. vanA has also been
shown to be present in normal fecal enterococci of
healthy, nonhospitalized persons in different
parts of Europe (66-68); in one study, 20 different
strains (identified by PFGE) of vancomycin-
resistant  E. faecium were found in the fecal flora
of 17 persons in two areas in Belgium (68). vanA
containing E. faecium have also been found in the
feces of healthy animals as well as from animal
products in Europe (50,67,69-71); in one study,
VRE were found in the feces of healthy meat-
eaters but not vegetarians (72). VRE have not,
however, been found as part of the normal fecal
flora in the United States (73) possibly because
glycopeptides, often used in animal feed in
Europe, are not used in the United States. For
example, 24,000 kg annually of the glycopeptide
avoparcin were reportedly used in recent years in
Denmark (74). Reports of VRE in the feces of
animals on farms using glycopeptides, but not in
those without such use, support this hypothesis
(71,75). While oral glycopeptide use markedly
increases the numbers of VRE per gram of stool in
humans (68) and by analogy, presumably does so
in animals, glycopeptide use does not explain the
origin of these gene clusters.
The problem of multidrug-resistant entero-
cocci promises to be with us for the foreseeable
future. The enterococcus has likely emerged as a
major nosocomial pathogen in part because of its
resistance to multiple antibiotics, which allows it
to survive and subsequently infect patients. With
its propensity to acquire new traits, such as high-
level gentamicin, penicillin, and vancomycin
resistance, the enterococcus continues to create
new therapeutic problems and dilemmas; its
ability to transfer some of its plasmids to
streptococci and staphylococci and the implica-
tions of a possible spread of penicillin and
vancomycin resistance to these and other gram-
positive species are also of concern.
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